Prescribing by international non-proprietary name, pharmacist incentives, and the high price differential between the brands and their generic alternatives are the key drivers of the generics market in the UK.
While biosimilars uptake has been slow initially, inclusion into hospital tenders and protocols is driving uptake for biosimilars of some product classes, while those used in the outpatient sector still have low use.
Table of Contents
4 EXECUTIVE SUMMARY
4 Generics market
4 Biosimilars market
5 GENERICS MARKET DYNAMICS
6 UK generics volume market share
7 UK generics value market share
8 UK generics market size
9 Bibliography
11 GENERICS DRIVERS AND RESISTORS
11 The proportion of generic drugs prescribed and dispensed has been steadily rising
12 Price differentials and physician prescribing behind growth in generics
13 Moves to encourage generic use have had mixed results
14 Other efforts have been made to boost generic use
15 Bibliography
17 BIOSIMILAR MARKET DYNAMICS
17 Biosimilar market drivers and resistors in the UK
21 Availability of biosimilars in the UK
25 Opportunities for the biosimilars industry
28 Bibliography
List of Figures
7 Figure 1: UK – comparison of generics volume market share versus other major
pharmaceutical markets (%), 2009–11
7 Figure 2: UK – comparison of generics value market share versus other major pharmaceutical
markets (%), 2009–11
8 Figure 3: UK – comparison of generics market size versus other major pharmaceutical markets
($bn), 2009–11
11 Figure 4: UK – key factors influencing the UK generics industry
27 Figure 5: Drivers of and resistors to biosimilar monoclonal antibody entry
List of Tables
5 Table 1: UK – comparison of generic penetration versus other major pharmaceutical markets
($bn and %), 2009–11
21 Table 2: Biosimilars approved and rejected in Europe to May 2013

Figure 1: UK – comparison of generics volume market share versus other major